Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 12/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904499 | 0.95 | AURKA (0.42) | AURKAPTPN11AADATEGFRTNK2 | |
| SCHEMBL1902096 | 0.93 | PTPN11 (0.39) | AURKAPTPN11MAT2AEGFRTNK2 | |
| SCHEMBL12677029 | 0.92 | AURKA (0.47) | AURKAPTPN11MAT2AEGFRTNK2 | |
| SCHEMBL1904033 | 0.92 | AURKA (0.37) | AURKAPTPN11EGFRTNK2TACR3 | |
| SCHEMBL14235581 | 0.91 | AURKA (0.46) | AURKAPTPN11MAT2AEGFRTNK2 | |
| SCHEMBL14119006 | 0.91 | AURKA (0.42) | AURKAPTPN11AADATTACR1KCNH2 | |
| SCHEMBL12095314 | 0.86 | AURKA (0.48) | AURKAPTPN11 | |
| SCHEMBL1900318 | 0.86 | FAP (0.34) | AURKAPTPN11TNK2LCK | |
| SCHEMBL1902107 | 0.86 | AKT1 (0.40) | AURKAPTPN11AADATEGFRTNK2 | |
| SCHEMBL1902109 | 0.86 | AKT1 (0.40) | AURKAPTPN11AADATEGFRTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AURKA 527/4885PTPN11 1410/4885MAT2A 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.